Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific celebrates CE mark breakthrough for its ProAxsis unit

"This is a very proud day for everyone at ProAxsis," said Dr David Ribeiro, CEO of ProAxsis
Chronic obstructive pulmonary disease
Neutrophil elastase is a well-recognised biomarker of lung inflammation

NetScientific PLC (LON:NSCI) said ProAxsis, its medical diagnostics company, has successfully registered a CE Mark for its novel ProteaseTag Active Neutrophil Elastase Immunoassay.

The healthcare intellectual property commercialisation group said the breakthrough will enable its Northern Ireland-based portfolio company to proceed to the commercialisation stage of its biochemical test in the European Union.

“We are delighted that ProAxsis has achieved a significant milestone in successfully CE marking its novel ProteaseTag Active Neutrophil Elastase Immunoassay for chronic respiratory diseases. This will help accelerate its commercialisation in the COPD and Cystic Fibrosis markets,” said François Martelet, chairman of ProAxsis and chief executive officer of NetScientific.

"ProAxsis is now able to sell its immunoassay in the 28 member states of the European Union, as well as Switzerland, Turkey, Iceland, Norway and Liechtenstein. Achieving CE Mark for its immunoassay demonstrates the company's clear commitment to delivering first-class quality products to physicians and their patients who suffer from chronic respiratory diseases," Martelet said.

Dr David Ribeiro, chief executive officer of ProAxsis, said the company had already had enquiries from a number of pharmaceutical companies concerning the commercial use of the immunoassay in their upcoming clinical trials.

John-H.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug
Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen
genomics.jpg
October 04 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use